Merck expands oncology pipeline with Harpoon acquisition

9 January 2024
harpoon_therapeutics_company

US pharma giant Merck & Co (NYSE: MRK) entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon Therapeutics (Nasdaq: HARP) for $23.00 per share.

Harpoon’s shares shot up 112% to $22.36 following the announcement that was made at the ongoing JP Morgan conference.

Harpoon’s board has unanimously approved the transaction, which has an equity value of around $680 million and is expected to close in the first half of 2024.The $23 per share offer represents a 118% premium to the stock's last close on Friday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology